10x Genomics

10x Genomics, Inc.
Industry Biotechnology
Founded 2012
Founder
  • Serge Saxonov
  • Ben Hindson
Headquarters Pleasanton, California, U.S.
Key people
Ben Hindson (President & CSO)
Website www.10xgenomics.com

10x Genomics, Inc. is an American company incorporated in 2012 that develops and manufactures integrated systems for whole genome sequencing, exome sequencing and single cell transcriptomics. Its headquarters are located in Pleasanton, California.

History

10x Genomics was founded in 2012 by Serge Saxonov and Ben Hindson, who previously worked at Quantalife. The company raised $110 million in equity through two rounds of investment in 2015 and 2016.[1][2] 10x Genomics made its public début at the JP Morgan Healthcare Conference in San Francisco in 2015. In November 2016, 10x Genomics was identified as one of the key players in the next generation sequencing (NGS) global market.[3]

Technology

The 10x platform uses a method based on emulsion PCR in order to produce "synthetic" long reads.[4][5] The 10x GemCode partitions arbitrarily large DNA fragments into micelles, along with an adapter molecule and a barcode sequence. Within each micelle, the gel bead dissolves, before smaller fragments of DNA are amplified from the large fragment. Each of the smaller fragments retain the barcode sequence which is used to identify its parent micelle. After amplification, the emulsion is broken and the DNA pooled, where it undergoes a standard library. preparation. After DNA sequencing, the reads are aligned and linked to form a series of fragments covering around 50kb. In contrast to the Illumina short read platform, this approach does not yield full coverage of a DNA fragment. Instead, the reads from a single micelle are dispersed across the original fragment; read coverage arises through the process being applied to very large numbers of micelles.[4]

Products

The original 10x Genomics sequencing platform, the GemCode, was officially launched in February 2015.[6] In February 2016, 10x Genomics announced the launch of its successor, the Chromium.[7]

References

  1. Timmerman, Luke. "Stealthy 10X Genomics Raises $55.5M To Beef Up DNA Sequencing". Forbes. Retrieved 8 November 2016.
  2. "10X Genomics | crunchbase". www.crunchbase.com. Retrieved 8 November 2016.
  3. "Next Generation Sequencing Global market - Forecast to 2022 - Key Players are 10X Genomics, Biomerieux & Danaher Corporation - Research and Markets | Business Wire". www.businesswire.com. Retrieved 8 November 2016.
  4. 1 2 Goodwin, Sara; McPherson, John D.; McCombie, W. Richard (17 May 2016). "Coming of age: ten years of next-generation sequencing technologies". Nature Reviews Genetics. 17 (6): 333–351. doi:10.1038/nrg.2016.49.
  5. "10X Genomics Announces a High-Throughput Platform for Synthetic Long Reads". www.bio-itworld.com. Retrieved 9 November 2016.
  6. "10X Genomics at AGBT". Retrieved 9 November 2016.
  7. "10X Genomics Reveals Upgraded Platform with New Features for Single-Cell RNA Sequencing". www.bio-itworld.com. Retrieved 9 November 2016.

External links

10x Genomics company website

This article is issued from Wikipedia - version of the 11/12/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.